Current Strategies of Endocrine Therapy in Elderly Patients with Breast Cancer

Table 3

Clinical trials of neoadjuvant endocrine therapy in elderly patients with breast cancer.

Study	Design	Number of patients	Treatment	Primary end point	Results
PROACT [5]	Phase 3, randomized, double-blind	451	Anastrozole 1 mg versus tamoxifen 20 mg	OR	39.5 versus 35.4%; odds ratio 1.24	0.29
IMPACT [6]	Phase 3, randomized, double-blinded	330	Anastrozole 1 mg versus tamoxifen 20 mg versus anastrozole 1 mg + tamoxifen 20 mg	OR	37 versus 36 versus 39%
Z1031 [7]	Phase 2, randomized	374	Exemestane 25 mg versus letrozole 2.5 mg versus anastrozole 1 mg	OR	62.9 versus 74.8 versus 69.1%
Eiermann et al. [8]	Phase 3, randomized, double-blinded	337	Letrozole 2.5 mg versus tamoxifen 20 mg	OR	55% versus 36%	<0.001
Semiglazov et al. [9]	Phase 2, randomized	239	Anastrozole 1 mg or exemestane 25 mg versus doxorubicin + paclitaxel	OR	64.5 versus 63.6%	>0.5
GEICAM/2006-03 [10]	Phase 2, randomized	95	Exemestane 25 mg versus EC-T	OR	48 versus 66%	0.075

No, number; OR, objective response; EC-T, epirubicin and cyclophosphamide followed by docetaxel.